Study design and ethics
The study was designed as an assessor-blinded parallel-group randomised controlled trial. This study was approved by the Ethics Committee of the Weifang People’s Hospital (KYLL20221128-1). And the study was registered in Chinese Clinical Trial Registry (02/12/2022; Chinese Clinical Trial registry, No.ChiCTR2200066366). Written informed consent was obtained from all participants. The trial report complies with the Consolidated Standards of Reporting Trials (CONSORT) checklist.